3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
37
Active not recruiting
13
Terminated
12
Withdrawn
7
Unknown
5
Recruiting
4
No longer available
3
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Ameloblastoma
1
Interventions
Nivolumab
6
pembrolizumab
3
Specimen Handling
3
Ipilimumab
3
relatlimab
2
cemiplimab
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
vedolizumab
1
trametinib
1
toripalimab
1
sulforaphane
1
gadopiclenol
1
famitinib
1
anlotinib
1
X-Rays
1
Watchful Waiting
1
Ultraviolet Therapy
1
Toll-Like Receptor 1
1
Therapeutics
1
Temozolomide
1
Technetium
1
Standard of Care
1
Sentinel Lymph Node Biopsy
1
SHR-1701
1
Rehabilitation
1
Phototherapy
1
Photopheresis
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Melanoma
×
trametinib
×
Clear all
NCT05275374
2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2
Not yet recruiting
221 enrolled